Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a (14)C-microtracer and therapeutic dose in cancer patients

INTRODUCTION: Niraparib (Zejula™) is a poly(ADP-ribose) polymerase inhibitor recently approved by the US Food and Drug Administration for the maintenance treatment of patients with recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancer Chemother Pharmacol
Auteurs principaux: van Andel, L., Rosing, H., Zhang, Z., Hughes, L., Kansra, V., Sanghvi, M., Tibben, M. M., Gebretensae, A., Schellens, J. H. M., Beijnen, J. H.
Format: Artigo
Langue:Inglês
Publié: Springer Berlin Heidelberg 2017
Sujets:
Original Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5754411/
https://ncbi.nlm.nih.gov/pubmed/29043410
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-017-3455-x
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires